CureVac files patent infringement lawsuit against BioNTech over mRNA technology
Company is seeking ‘fair compensation’ for alleged infringement of intellectual property rights relating to the use of mRNA tech to create the Pfizer-BioNTech COVID-19 vaccine
CureVac has filed a patent infringement lawsuit in Germany against BioNTech over its use of messenger RNA (mRNA) technology, some of which was used to develop the Comirnaty coronavirus vaccine.
The German biopharma company filed the lawsuit against BioNTech SE and two of its subsidiaries in a Düsseldorf court, seeking ‘fair compensation for infringement of a portfolio of CureVac’s intellectual property rights’.
Speaking in a media call, CureVac CEO Franz-Werner Haas said the company was not ruling out further legal action against BioNTech partner Pfizer or rival mRNA vaccine maker Moderna.
BioNTech claims its work is original and said it would ‘vigorously defend it against all allegations of patent infringement’. The company also noted that it was ‘not unusual’ for companies to make such a claim, given the global success of the Comirnaty vaccine.
CureVac says its claim is based on ‘proprietary foundational technology related to mRNA design, delivery and manufacturing’ developed by the company over the course of 22 years and claims this technology ‘materially contributed to the development of safe and efficacious COVID-19 vaccines.’
In a statement on Tuesday, CureVac said it was the ‘earliest pioneer in mRNA technology’ and called for its intellectual property rights to be ‘acknowledged and respected in the form of fair compensation.’ The company also clarified that it was not seeking an injunction, nor intended to take legal action that would impede the production, sale or distribution of the Comirnaty vaccine.
The company did not disclose a sum they would consider as fair compensation.
This marks the second patent infringement lawsuit impacting a Pfizer-produced drug for use against COVID-19, after Enanta Pharmaceuticals announced legal action over the oral antiviral Paxlovid last month.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance